Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer
- 1 February 2020
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 206, 107437
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education (2016R1A6A1A03012862)
- Ministry of Science, ICT and Future Planning (2016R1A2B4016005)
- National Research Foundation of Korea
This publication has 110 references indexed in Scilit:
- Reduced Expression of miR-200 Family Members Contributes to Antiestrogen Resistance in LY2 Human Breast Cancer CellsPLOS ONE, 2013
- Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cellsCell Death & Disease, 2013
- CA 15-3: Uses and limitation as a biomarker for breast cancerClinica Chimica Acta, 2010
- miRNAs in human cancerThe Journal of Pathology, 2010
- Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor modelNature Biotechnology, 2010
- miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-α in human breast cancer cellsCell Death & Differentiation, 2009
- Suppression of cell growth and invasion by miR-205 in breast cancerCell Research, 2009
- MicroRNA expression profiles classify human cancersNature, 2005
- The Microprocessor complex mediates the genesis of microRNAsNature, 2004
- The functions of animal microRNAsNature, 2004